Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT-007: H101 + TACE followed by PD-1 inhibitor in unresectable hepatocellular carcinoma
ChiCTR2600123554Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Apr 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Oncorine in hepatocellular carcinoma (HCC), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Time to progression (TTP). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600123554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123554.